Subsequently, a decoy peptide based on the sequence of the HR was used as a prorenin blocker and was found to have a beneficial, inhibitory effect on diabetic retinopathy by mitigating the production of vascular endothelial growth factor (VEGF) and intercellular adhesion molecule-1 (ICAM-1) [6–9]. This evidence concerns the gene VEGFA and diabetic retinopathy.